Ultragenyx Pharmaceutical Q3 2026 earnings

RARE · 2026-11-03 16:07 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue declined sequentially and year-over-year, but the company announced substantial expense reductions and PRV sales to support a 2027 profitability target.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$173 million+8%-19%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
CRYSVITA$109 million-3%63%Latin America and Türkiye sales decreased; U.S. and Canada royalties increased
DOJOLVI$30 million+25%17%Japan launch and NHI listing
EVKEEZA$24 million+41%14%New country launches and early access
MEPSEVII$10 million+43%6%—

Margins and costs

  • Gross margin 18.5% (prior 15.7%, change +2.8 pp)
  • Operating expenses $283 million (+14% YoY)
  • One-offs in the quarter PRV sales: GENGLYCOS ($210 million), FAYUVI ($203 million); Restructuring: ~$25 million severance and other charges in Q4 2026
  • Effective tax rate 8% (prior-year -1%, year-to-date 2%)
  • Non-GAAP bridge No reconciliation provided in press release.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents, and marketable securities$401 million$436 million$737 million-8%
Net cash used in operations$43 million$97 million$-266 million—
R&D expenses (2027 guidance)<$350 million——-50% vs 2025
SG&A expenses (2027 guidance)<$375 million———

Guidance

MetricGuidePrior guideChange
Total revenue 2026$730 million to $760 million$730 million to $760 millionReaffirmed
Crysvita revenue 2026$500 million to $520 million$500 million to $520 millionReaffirmed
Dojolvi revenue 2026$100 million to $110 million$100 million to $110 millionReaffirmed
Full-year GAAP profitabilityExpected in 2027On path to profitability in 2027Reaffirmed

What drove it

  • Revenue story Total revenue declined 19% sequentially and 8% YoY to $173M. CRYSVITA revenue decreased 3% YoY to $109M, while DOJOLVI increased 25% YoY to $30M driven by Japan launch.
  • EPS story Net loss per share improved YoY and QoQ due to lower operating expenses and a tax benefit, despite lower revenue.
  • One-off check PRV sales: GENGLYCOS ($210M) and FAYUVI ($203M) closed in October 2026; Q4 2026 restructuring charges of ~$25M.

The good

  • Highest quarterly revenue in company history achieved in Q2 2026
  • Dojolvi revenue growth driven by Japan launch and NHI listing
  • PRV sales of $413M provide substantial cash proceeds

The bad

  • Total revenue declined sequentially and YoY
  • R&D expenses increased 14% YoY to $154M
  • Net loss per share widened sequentially despite lower YoY loss

The ugly

  • UX701 program terminated for Wilson disease as it did not meet study goals
  • GTX-102 Angelman syndrome studies are being wound down

Open questions

  • Specifics of the 2027 R&D expense reduction plan and timeline
  • Timing and amount of Q4 2026 restructuring charges
  • Impact of terminating UX701 and GTX-102 on the R&D pipeline
Full release

Ultragenyx Pharmaceutical (RARE) earnings release, November 3, 2026

Ultragenyx Pharmaceutical Inc. (RARE) · Form 8-K, Item 2.02 · Filed · SEC filing

Contacts Ultragenyx Pharmaceutical Inc.

Investors

Joshua Higa ir@ultragenyx.com

Media

Jess Rowlands media@ultragenyx.com

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

Third quarter total revenue of $173 million,

CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million

GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter

Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million

Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025

NOVATO, Calif. – November 03, 2026 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.

“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”

Third Quarter 2026 Revenue Highlights and 2026 Revenue Guidance

• Total revenue in the third quarter 2026 was $173 million. The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.

• CRYSVITA revenue in the third quarter 2026 was $109 million, consistent with expected ordering patterns. The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.

• DOJOLVI revenue in the third quarter 2026 was $30 million. The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.

• EVKEEZA® revenue in the third quarter 2026 was $24 million, driven by increased demand from new country launches and early access.

• MEPSEVII® revenue in the third quarter 2026 was $10 million.

Summary of Third Quarter 2026 Financial Results

Selected Financial Data (dollars in millions, except per share amounts), (unaudited)

Operating Expenses

Total operating expenses for the third quarter 2026 were $283 million, including $34 million of non-cash stock-based compensation.

Net Loss

Net loss for the third quarter 2026 was $118 million, or $1.16 per share basic and diluted, compared with a net loss for the third quarter 2025 of $180 million, or $1.81 per share basic and diluted.

Cash Balance and Net Cash Used in Operations

Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026. For the three months ended September 30, 2026, net cash used in operations was $43 million.

In October 2026, the Company entered into two definitive agreements to sell the PRVs received upon the approval of GENGLYCOS and FAYUVI for a combined price of $413 million. The sale of the GENGLYCOS PRV closed last week and the FAYUVI PRV sale is expected to close later this month. Net proceeds from both sales are expected to be approximately $350 million.

Initiation of substantial expense reductions and reaffirming profitability in 2027

With the recent completion of late-stage development programs, including first-ever FDA approvals in glycogen storage disease type Ia (GSDIa) and Sanfilippo syndrome type A, Ultragenyx is entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint. To support this transition, the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million and 2027 SG&A expenses to less than $375 million. Savings actions include:

• Reducing headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees

• Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome

• Terminating UX701 for Wilson disease based on not achieving study goals

• Reducing expenses across the company, including reduction of real estate footprint

In addition to executing these critical expense reductions, the company is focused on driving successful launches for GENGLYCOS and FAYUVI and continuing to grow current product revenues. R&D investments will be focused on delivering primary data from the responder endpoint of the ongoing Phase 3 study for DTX301 for ornithine² transcarbamylase deficiency, determining if there is a viable path forward for UX143 (setrusumab) for osteogenesis imperfecta, and measured spending to progress early-stage programs for future INDs.

Fourth quarter 2026 financial results are expected to include approximately $25 million of severance and other non-recurring restructuring charges, and the reduction in force is expected to be substantially completed by the end of 2026. The company continues to anticipate achieving full-year GAAP profitability in 2027 and going forward.

Recent Corporate Updates and Upcoming Milestones

• GENGLYCOS (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa):

In August 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval for GENGLYCOS as a treatment for adult and pediatric patients eight years and older with GSDIa. The company received a PRV upon this approval and sold it for $210 million.

• FAYUVI (rebisufligene etisparvovec) AAV9 gene therapy for the treatment of Sanfilippo syndrome type A (MPS IIIA):... (truncated)rd full approval for FAYUVI as a treatment of pediatric patients with Sanfilippo syndrome Type A. The company received a PRV upon this approval and, in October 2026, entered into a definitive agreement to sell the PRV for $203 million.

• UX701 (rivunatpagene miziparvovec) AAV9 gene therapy for the treatment of Wilson disease:

Additional data in the dose-finding stage of the

Cyprus2+ study of UX701 for the treatment of Wilson disease, including data from the fourth dosing cohort, demonstrated clinical activity in some patients, but did not meet the criteria that the majority of patients achieve biochemical response and elimination of standard of care, to advance the program to the pivotal Phase 3, stage of development. UX701 demonstrated a favorable safety profile across all cohorts dosed. Data from the completed study is expected to be presented at an upcoming medical or scientific congress.

The company will terminate further development of this program and is working with clinical sites and patient advocacy groups to support the patient community through this transition.

• UX016 novel prodrug for sialic acid used as a substrate replacement therapy for the treatment of GNE myopathy:

The Phase 1/2 study is evaluating safety and dose of UX016 and its impact on muscle strength in adults with GNEM. The UX016 program is fully funded through clinical proof-of-concept by an external venture philanthropy agreement with a patient group, which supports all costs for the Phase 1/2 study and dosing will be initiated soon.

• DTX301 (avalotcagene ontaparvovec) AAV8 gene therapy for the treatment of Ornithine Transcarbamylase, or OTC, deficiency:

The Phase 3

Enh3ance placebo-controlled study showed substantial improvement in ammonia control and reduction in the need for scavenger medicines along with profound improvement in global impression scale. The study continues with patients in both treatment and cross-over groups progressing through 64 weeks of follow-up to evaluate the second primary endpoint of the reduction in the use of ammonia scavengers and dietary management. Data are expected in the first half of 2027.

• UX143 (setrusumab) monoclonal antibody for the treatment of osteogenesis imperfecta:

Phase 3 data with pre- and post-hoc analyses were presented at the American Society for Bone and Mineral Research 2026 Annual Meeting showing a meaningful benefit on bone mineral density, fractures, and other endpoints in the two Phase 3 studies. The company will continue to engage regulatory agencies to determine the necessary data to support a regulatory filing and if there is a potential path forward for UX143.³

Conference Call and Webcast Information

Ultragenyx will host a conference call today, Tuesday, November 3, 2026, at 2 p.m. PT/5 p.m. ET to discuss the third quarter financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Financial statements

Income Statement

Three Months Ended September 30, — Selected Financial Data (dollars in millions, except per share amounts), (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Total revenues173160523466
Operating expenses:
Cost of sales32289680
Research and development154216508547
Selling, general and administrative9787273261
Total operating expenses283331877888
Net loss-118-180-395-446
Net loss per share, basic and diluted-1.16-1.81-3.89-4.55

Income Statement

Three Months Ended September 30, — (unaudited) (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CRYSVITA
Product sales - Latin America and Türkiye4147141137
Royalty revenue - U.S. and Canada6157194177
Royalty revenue - Europe782322
Total CRYSVITA Revenue109112358336
DOJOLVI30247564
EVKEEZA24176342
MEPSEVII1072724
Total revenues173160523466

Income Statement

Three Months Ended September 30, — (unaudited) (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
Product sales10595306267
Royalty revenue6865217199
Total revenues173160523466
Operating expenses:
Cost of sales32289680
Research and development154216508547
Selling, general and administrative9787273261
Total operating expenses283331877888
Loss from operations-110-171-354-422
Non-cash interest expense on liabilities for sales of future royalties-20-14-63-42
Other income, net361521
Loss before income taxes-127-179-402-443
Benefit from (provision for) income taxes9-17-3
Net loss-118-180-395-446
Net loss per share, basic and diluted-1.16-1.81-3.89-4.55
Shares used in computing net loss per share, basic and diluted102.199.8101.698.2

Balance Sheet

September 30, — (unaudited) (in millions)

September 30, – 2026December 31, – 2025
Balance Sheet Data:
Cash, cash equivalents, and marketable securities401737
Working capital155567
Total assets1,1871,532
Total stockholders' deficit-376-80

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (In millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities:
Net loss-395-446
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation98116
Amortization of discount on marketable securities, net-1-4
Depreciation and amortization2526
Non-cash royalty revenue-81-74
Non-cash interest expense on liabilities for sales of future royalties6342
Deferred income taxes-10
Other-2-3
Changes in operating assets and liabilities:
Accounts receivable-203
Inventory-8-6
Prepaid expenses and other assets2-7
Accounts payable, accrued, and other liabilities-8-13
Net cash used in operating activities-337-366
Investing activities:
Purchase of property, plant, and equipment-4-5
Purchase of marketable securities-227-32
Proceeds from sale of marketable securities91
Proceeds from maturities of marketable securities200362
Payments for intangible asset-5-15
Other-2-2
Net cash provided by investing activities53308
Financing activities:
Proceeds from issuance of simple agreements for future equity, or SAFEs10
Proceeds from the issuance of common stock under equity plans, net34
Proceeds from the issuance of common stock in connection with at-the-market offering, net80
Net cash provided by financing activities1384
Effect of exchange rate changes on cash-15

Forward-Looking Statements and Use of Digital Media

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Ultragenyx’s expectations and projections concerning its future operating results and financial performance, including its 2026 revenue guidance for total revenue, Crysvita and Dojolvi, its anticipated R&D and SG&A expenses in 2027, the expected timing of closing and net proceeds from the sales of its PRVs, the anticipated scope, timing, costs, benefits and savings of its headcount and expense reductions, including expected severance and other restructuring charges and the expected timing of completion of the reduction in force, and the timing and sustainability of profitability, including expected full-year GAAP profitability in 2027 and going forward; the timing, progress, results and plans for its clinical programs and studies, including the wind-down of the GTX-102 studies, the termination of the UX701 program, the anticipated timing of data from the Phase 3 Enh3ance study of DTX301, engagement with regulatory agencies regarding UX143 and whether there is a potential path forward for UX143, and initiation of dosing in the UX016 study; Ultragenyx’s ability to successfully launch and commercialize GENGLYCOS and FAYUVI, demand for these products, and Ultragenyx’s ability to satisfy post-marketing requirements, including confirmatory study requirements associated with the accelerated approval of GENGLYCOS; and the potential patient impact, commercial opportunity and growth associated with Ultragenyx’s products and product candidates, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause the company’s clinical development programs, commercial success of its products and product candidates, continued collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals, the risk that the FDA may withdraw the accelerated approval of GENGLYCOS if confirmatory studies do not verify clinical benefit, risks related to serious or undesirable side effects of our products and product candidates, the company’s ability to achieve its projected development goals in its expected timeframes, risks related to reliance on third party partners to conduct certain activities on the company’s behalf, our limited experience in launching and commercializing gene therapy products, risks related to product liability lawsuits, our dependence on Kyowa Kirin for the commercialization of Crysvita in certain major markets, including the U.S. and Canada, and for our commercial supply of Crysvita in those markets, fluctuations in buying or distribution patterns from distributors and specialty pharmacies, smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, the risk that the PRV sales may not close on the expected timeline or at all, delays or unexpected costs and other adverse effects related to the headcount and expense reductions, including disruption to our operations and our ability to retain key employees, competition from other therapies or products, regulatory scrutiny of the company’s products and product candidates, the⁴ company’s limited experience as a company in operating its own manufacturing facility, market acceptance of our products, uncertainty related to insurance coverage and reimbursement, and other matters that could affect sufficiency of existing cash, cash equivalents and marketable securities to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and product candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2026, and its subsequent periodic reports filed with the SEC.

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website

(https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).

###⁵

Ultragenyx Pharmaceutical Inc.

Selected Revenue Data

(in millions)

(unaudited)

Ultragenyx Pharmaceutical Inc.

Selected Statement of Operations Financial Data

(in millions, except per share amounts)

(unaudited)⁶

Ultragenyx Pharmaceutical Inc.

Selected Activity included in Operating Expenses

(in millions)

(unaudited)

Ultragenyx Pharmaceutical Inc.

Selected Balance Sheet Financial Data

(in millions)

(unaudited)⁷

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.